Clinical reference Biomarker Directory
Back to directory

LYZ

Emerging

Lysozyme supports sarcoidosis diagnosis and is elevated in monocytic leukemias, where very high levels can injure the kidneys.

Also known as Lysozyme muramidase
In plain language

Lysozyme is an antibacterial enzyme released by certain white blood cells. High levels can support a sarcoidosis diagnosis and are also seen in certain leukemias, where very high levels can even harm the kidneys directly.

Biomarker & context

Lysozyme is an antimicrobial enzyme produced by monocytes and macrophages that breaks down bacterial cell walls, used as a supportive biomarker in a few distinct clinical contexts.

What it indicates

Elevated serum lysozyme is a classic supporting marker for sarcoidosis, reflecting granuloma burden similarly to ACE (discussed much earlier), and is also elevated in monocytic and myelomonocytic leukemias.

Diagnosis & clinical testing

Measured via serum immunoassay; in leukemia, very high lysozyme levels can themselves contribute to kidney tubular injury, an important secondary complication to monitor in monocytic leukemia patients with markedly elevated levels.

Guiding treatment

Elevated lysozyme in sarcoidosis is followed similarly to ACE, tracking disease activity and treatment response; in monocytic leukemia, extremely high levels warrant monitoring for lysozyme-induced kidney injury.

Clinical significance

A secondary complication in monocytic leukemia: lysozyme-induced kidney tubular injury at very high levels.

References
  1. General reference literature on lysozyme in sarcoidosis and monocytic leukemia-associated kidney injury.